Product Description
Azasetron (Serotone) is a potent and selective 5-HT3 receptor antagonist, and classified as benzamide derivative. It has a different chemical structure from indole-type 5-HT3 receptor antagonists such as granisetron, ondansetron, ramosetron and tropisetron. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10396331/)
Mechanisms of Action: 5-HT3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Sensorion
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hearing Loss
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05628233 |
NOTOXIS | P2 |
Completed |
Hearing Loss |
2025-04-16 |
2026-07-03 |
Primary Endpoints |
|
2024-511713-38-00 |
SENS-401-202 | P2 |
Recruiting |
Hearing Loss |
2025-03-31 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/11/2019 |
News Article |
Sensorion Announces Three Presentations at IEB 2019 in Padua |
|
06/28/2019 |
News Article |
Sensorion Receives European Medicines Agency Agreement on the Pediatric Investigation Plan (PIP) for Arazasetron (SENS-401) in Two Indications |